Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step
- PMID: 29122378
- DOI: 10.1016/j.eururo.2017.10.016
Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step
Comment on
-
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.Eur Urol. 2018 Jul;74(1):17-23. doi: 10.1016/j.eururo.2017.08.035. Epub 2017 Sep 20. Eur Urol. 2018. PMID: 28939004 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
